Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
Details : Through the collaboration, both companies will leverage Alphamab’s proprietary linker-payload platform and glycan-conjugation technology to identify novel ADCs for oncology indications.
Brand Name : Undiclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 05, 2024
Lead Product(s) : JSKN003
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Alphamab to Present Data of JSKN003 for HER2-expressing Solid Tumors at ASCO 2024
Details : JSKN003 is an anti-HER2 bispecific antibody-drug conjugate, which is currently being evaluated for the treatment of HER2-expressing advanced solid tumors.
Brand Name : JSKN003
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 06, 2024
Lead Product(s) : JSKN003
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Envafolimab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Glenmark, Jiangsu Alphamab, and 3D Medicines Sign License Agreement for KN035
Details : Glenmark is responsible for developing, registering, and commercializing KN035 (envafolimab) outside of China for MSI-H or dMMR advanced solid tumors in previously treated adults.
Brand Name : KN035
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 25, 2024
Lead Product(s) : Envafolimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Envafolimab,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : TRACON Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KN035 (envafolimab) is a single-domain antibody against PD-L1 invented by Alphamab Oncology and licensed by TRACON, is the first approved subcutaneously injected PD-(L)1 inhibitor, which is investigated for MSI-H/dMMR advanced solid tumors.
Brand Name : KN035
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 20, 2023
Lead Product(s) : Envafolimab,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : TRACON Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Envafolimab,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : TRACON Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Result demonstrated highly tolerable safety profile and significantly higher objective response rate observed in lower weight patients in ENVASARC, to increase dose of envafolimab to 600 mg every three weeks, which is double the original envafolimab dose...
Brand Name : KN035
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 19, 2022
Lead Product(s) : Envafolimab,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : TRACON Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KN046-204 is a phase II clinical study in China to evaluate the efficacy and safety of KN046 monotherapy or plus chemotherapy for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Brand Name : KN046
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 07, 2021
Lead Product(s) : KN046,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KN046-203 is a phase Ib/II, open label, multi-center clinical study, evaluating the efficacy, safety, and tolerability of KN046 in combination with nab-paclitaxel in patients with TNBC.
Brand Name : KN046
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 13, 2021
Lead Product(s) : KN046,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KN046 is a bispecific antibody targeting PD-L1 and CTLA-4 immune checkpoints. Alphamab will conduct a open label, multi-center phase II pivotal clinical study in the U.S to evaluate the efficacy, safety and tolerability of KN046 for the treatment of thy...
Brand Name : KN046
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 09, 2021
Details : The recombinant humanized PD-L1/ CTLA-4 bispecific antibody KN046 was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of thymic epithelial tumors.
Brand Name : KN046
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 03, 2020
Lead Product(s) : COVID-19 neutralizing antibody
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Institut Pasteur Shanghai
Deal Size : Undisclosed
Deal Type : Partnership
Details : According to the agreement, Alphamab Oncology and Institut Pasteur Shanghai will form a joint project team. Alphamab Oncology is responsible for providing its proprietary Mixed Antibodies Platform, constructing humanized antibodies and recombinant engine...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 10, 2020
Lead Product(s) : COVID-19 neutralizing antibody
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Institut Pasteur Shanghai
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?